240 related articles for article (PubMed ID: 31280933)
1. Predicting drug-free remission in rheumatoid arthritis: A prospective interventional cohort study.
Baker KF; Skelton AJ; Lendrem DW; Scadeng A; Thompson B; Pratt AG; Isaacs JD
J Autoimmun; 2019 Dec; 105():102298. PubMed ID: 31280933
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics associated with drug-free sustained remission in patients with rheumatoid arthritis: Data from Korean Intensive Management of Early Rheumatoid Arthritis (KIMERA).
Jung SM; Pyo JY; Lee SW; Song JJ; Lee SK; Park YB
Semin Arthritis Rheum; 2020 Dec; 50(6):1414-1420. PubMed ID: 32241617
[TBL] [Abstract][Full Text] [Related]
3. Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms.
Ajeganova S; van Steenbergen HW; van Nies JA; Burgers LE; Huizinga TW; van der Helm-van Mil AH
Ann Rheum Dis; 2016 May; 75(5):867-73. PubMed ID: 25972519
[TBL] [Abstract][Full Text] [Related]
4. Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept.
Ahmad HA; Baker JF; Conaghan PG; Emery P; Huizinga TWJ; Elbez Y; Banerjee S; Østergaard M
Arthritis Res Ther; 2022 Feb; 24(1):47. PubMed ID: 35172859
[TBL] [Abstract][Full Text] [Related]
5. Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial.
Kjørholt KE; Sundlisæter NP; Aga AB; Sexton J; Olsen IC; Fremstad H; Spada C; Madland TM; Høili CA; Bakland G; Lexberg Å; Hansen IJW; Hansen IM; Haukeland H; Ljoså MA; Moholt E; Uhlig T; Kvien TK; Solomon DH; van der Heijde D; Haavardsholm EA; Lillegraven S
Lancet Rheumatol; 2024 May; 6(5):e268-e278. PubMed ID: 38583450
[TBL] [Abstract][Full Text] [Related]
6. Circulating calprotectin (S100A8/A9) is higher in rheumatoid arthritis patients that relapse within 12 months of tapering anti-rheumatic drugs.
de Moel EC; Rech J; Mahler M; Roth J; Vogl T; Schouffoer A; Goekoop RJ; Huizinga TWJ; Allaart CF; Toes REM; Schett G; van der Woude D
Arthritis Res Ther; 2019 Dec; 21(1):268. PubMed ID: 31805992
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts.
van der Woude D; Young A; Jayakumar K; Mertens BJ; Toes RE; van der Heijde D; Huizinga TW; van der Helm-van Mil AH
Arthritis Rheum; 2009 Aug; 60(8):2262-71. PubMed ID: 19644846
[TBL] [Abstract][Full Text] [Related]
8. Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care: characteristics and predictors.
Terslev L; Ostergaard M; Georgiadis S; Brahe CH; Ellegaard K; Dohn UM; Fana V; Møller T; Juul L; Huynh TK; Krabbe S; Ornbjerg LM; Glinatsi D; Røgind H; Hansen A; Nørregaard J; Jacobsen S; Jensen DV; Manilo N; Asmussen K; Boesen M; Rastiemadabadi Z; Morsel-Carlsen L; Møller JM; Krogh NS; Hetland ML
RMD Open; 2022 Dec; 8(2):. PubMed ID: 36549857
[TBL] [Abstract][Full Text] [Related]
9. Prediction of disease flare by biomarkers after discontinuing biologics in patients with rheumatoid arthritis achieving stringent remission.
Kameda H; Hirata A; Katagiri T; Takakura Y; Inoue Y; Takenaka S; Ito H; Mizushina K; Ogura T
Sci Rep; 2021 Mar; 11(1):6865. PubMed ID: 33767314
[TBL] [Abstract][Full Text] [Related]
10. Prediction of DAS28-CRP remission in patients with rheumatoid arthritis treated with tacrolimus at 6 months by baseline variables.
Aramaki T; Kawakami A; Iwamoto N; Fujikawa K; Kawashiri SY; Tamai M; Arima K; Kamachi M; Yamasaki S; Nakamura H; Nakashima M; Mizokami A; Furuyama M; Matsuoka N; Ueki Y; Ida H; Origuchi T; Aoyagi K; Eguchi K
Mod Rheumatol; 2009; 19(6):652-6. PubMed ID: 19787419
[TBL] [Abstract][Full Text] [Related]
11. Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort.
Rannio T; Asikainen J; Hannonen P; Yli-Kerttula T; Ekman P; Pirilä L; Kuusalo L; Mali M; Puurtinen-Vilkki M; Kortelainen S; Paltta J; Taimen K; Kauppi M; Laiho K; Nyrhinen S; Mäkinen H; Isomäki P; Uotila T; Aaltonen K; Kautiainen H; Sokka T
Scand J Rheumatol; 2017 Nov; 46(6):425-431. PubMed ID: 28367663
[TBL] [Abstract][Full Text] [Related]
12. Chinese registry of rheumatoid arthritis (CREDIT): III. The transition of disease activity during follow-ups and predictors of achieving treatment target.
Xiang Y; Wang Q; Li H; Duan X; Fang Y; Yang P; Li Q; Wu R; Huo Y; Shi X; Wu Z; Wang Y; Jiang N; Hsieh E; Li M; Tian X; Zeng X;
Int J Rheum Dis; 2020 Dec; 23(12):1719-1727. PubMed ID: 33034424
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trial.
Brahe CH; Østergaard M; Johansen JS; Defranoux N; Wang X; Bolce R; Sasso EH; Ørnbjerg LM; Hørslev-Petersen K; Stengaard-Pedersen K; Junker P; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Lottenburger T; Ammitzbøll C; Jørgensen A; Krintel SB; Raun J; Hetland ML
Scand J Rheumatol; 2019 Jan; 48(1):9-16. PubMed ID: 29985080
[TBL] [Abstract][Full Text] [Related]
14. A multi-biomarker disease activity score can predict sustained remission in rheumatoid arthritis.
Ma MHY; Defranoux N; Li W; Sasso EH; Ibrahim F; Scott DL; Cope AP
Arthritis Res Ther; 2020 Jun; 22(1):158. PubMed ID: 32580789
[TBL] [Abstract][Full Text] [Related]
15. Serum soluble interleukin-2 receptor predicts early remission in patients with recent-onset rheumatoid arthritis treated with a single disease-modifying antirheumatic drug.
Kuuliala A; Leirisalo-Repo M; Möttönen T; Hannonen P; Nissilä M; Kautiainen H; Korpela M; Julkunen H; Hakola M; Repo H;
Clin Exp Rheumatol; 2005; 23(2):243-6. PubMed ID: 15895898
[TBL] [Abstract][Full Text] [Related]
16. Clinical deep remission and related factors in a large cohort of patients with rheumatoid arthritis.
Liu JJ; Li R; Gan YZ; Zhang RJ; Li J; Cai YM; Zhao JX; Liao H; Xu J; Shi LJ; Li J; Li SG; Sun XL; He J; Liu X; Ye H; Li ZG
Chin Med J (Engl); 2019 May; 132(9):1009-1014. PubMed ID: 30946065
[TBL] [Abstract][Full Text] [Related]
17. Does immunological remission, defined as disappearance of autoantibodies, occur with current treatment strategies? A long-term follow-up study in rheumatoid arthritis patients who achieved sustained DMARD-free status.
Boeters DM; Burgers LE; Toes RE; van der Helm-van Mil A
Ann Rheum Dis; 2019 Nov; 78(11):1497-1504. PubMed ID: 31413004
[TBL] [Abstract][Full Text] [Related]
18. The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis.
Tanaka Y; Smolen JS; Jones H; Szumski A; Marshall L; Emery P
Arthritis Res Ther; 2019 Jul; 21(1):164. PubMed ID: 31277720
[TBL] [Abstract][Full Text] [Related]
19. Predictors of flare in rheumatoid arthritis patients with persistent clinical remission/low disease activity: Data from the TARAC cohort.
Chaiamnuay S; Jiemjit S; Songdechaphipat W; Narongroeknawin P; Pakchotanon R; Asavatanabodee P
Medicine (Baltimore); 2022 Aug; 101(32):e29974. PubMed ID: 35960097
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of abatacept tapering therapy for sustained remission in patients with rheumatoid arthritis: Prospective single-center study.
Yoshida S; Kotani T; Kimura Y; Matsumura Y; Yoshikawa A; Tokai N; Ozaki T; Nagai K; Takeuchi T; Makino S; Arawaka S
Int J Rheum Dis; 2019 Jan; 22(1):81-89. PubMed ID: 30168272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]